Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  Applied DNA Sciences Inc    

APPLIED DNA SCIENCES INC
Mes dernières consult.
Most popular
Report
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Applied DNA Sciences Inc : Applied DNA Sciences Continues Expansion in Sweden

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/11/2012 | 04:40am CET
Applied DNA Sciences Continues Expansion in Sweden Security Giant Nokas Adopts DNA Evidentiary Marking

MEDIA CONTACT: Mitchell Miller, 646-543-3373, fax: 631-444-8848

INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848

FCMN Contact: [email protected]

PROGRAM CONTACT: Leif Svensson, CEO, Safe Solution AB, +46 76-774 44 14

Web site: http://www.adnas.com

Twitter: @APDN, @APDNInvestor

STONY BROOK, NY, December 10, 2012. Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today that its evidentiary DNA platform has been adopted in Sweden for use in helping protect cash in transit in that country. The security company Nokas AS revealed that APDN's marking and authentication

platform will first be deployed in armored vehicles in the Stockholm area and then expanded to the company's
entire fleet.
The technology comes into play during a robbery, when botanically-based DNA marks within a water-based spray are released on cash notes and the criminals themselves. The marks can survive on the notes, clothes, and skin for long periods of time. In court, they provide accepted evidence directly linking criminals to the crime.
Nokas, based in Norway, fields a fleet of over 250 armored trucks to transport cash. It is one of only two cash transport companies in Sweden servicing many retail chains, large banks and other institutions.
The APDN platform for cash in transit already has been used with great success in the United Kingdom, where DNA evidence has helped in over fifty convictions of armed and dangerous criminals since 2009, in an environment where front-line police and private guards are typically unarmed. The DNA marking and authentication platform protects more than 26% of cash being transported to and from banks in the United Kingdom.
Johan Petersson, Nokas security officer, commented, "This is an exciting development for the entire security industry. We are the first with new technology in cash in transit in this region, which helps deter crime and helps the judiciary to prosecute any offense. Using this new technology, Nokas will provide added security to its staff and customers. We believe we are at the forefront."
Elsewhere in Sweden, adoption of the APDN DNA platform has been expanding.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on APPLIED DNA SCIENCES INC
01/23 APPLIED DNA SCIENCES : Expands Internationally with New Central DNA Testing Labo..
01/18 APPLIED DNA SCIENCES : Introduces “GeoTyping” Beta Program Through F..
01/16 APPLIED DNA SCIENCES INC : Free Post Earnings Research Report: Applied DNA Repor..
01/11 APPLIED DNA SCIENCES : SigNature® DNA Evidence by Applied DNA Used to Convict Cr..
01/04 APPLIED DNA SCIENCES : Reports Year End and Fiscal Fourth Quarter Results
01/03 APPLIED DNA SCIENCES : SigNature® DNA Evidence by Applied DNA Used to Convict Cr..
2017 APPLIED DNA SCIENCES, INC. (NASDAQ : APDN) Files An 8-K Results of Operations an..
2017 APPLIED DNA SCIENCES INC : Results of Operations and Financial Condition, Financ..
2017 APPLIED DNA SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
2017 APPLIED DNA SCIENCES : reports 4Q loss
More news
Financials ($)
Sales 2018 11,6 M
EBIT 2018 -7,90 M
Net income 2018 -7,95 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 3,68x
Capi. / Sales 2019 2,10x
Capitalization 42,7 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 5,00 $
Spread / Average Target 221%
EPS Revisions
Managers
NameTitle
James A. Hayward Chairman, President & Chief Executive Officer
Beth Jantzen Chief Financial Officer & Controller
Ming-Hwa Benjamin Liang Secretary & Chief Scientific Officer
Judith Murrah Chief Information Officer
Sanford R. Simon Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
APPLIED DNA SCIENCES INC43
ECOLAB4.15%39 801
SIKA7.82%18 737
SYMRISE-3.66%11 031
CLARIANT7.82%10 085
INDORAMA VENTURES PCL--.--%9 524